[1]陈丰 苏强 朱继金.高迁移率族蛋白B1在心脏炎症反应性疾病中的研究进展[J].心血管病学进展,2019,(8):1111-1114.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
　CHEN Feng,SU Qiang,ZHU Jijin.Research Progress of HMGB1 in Myocardial Inflammatory Reactivity Disease[J].Advances in Cardiovascular Diseases,2019,(8):1111-1114.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
点击复制

高迁移率族蛋白B1在心脏炎症反应性疾病中的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2019年8期
页码:
1111-1114
栏目:
综述
出版日期:
2019-11-25

文章信息/Info

Title:
Research Progress of HMGB1 in Myocardial Inflammatory Reactivity Disease
作者:
陈丰1 苏强2 朱继金1; 2
(1.广西医科大学研究生院,广西 南宁 530021;2.广西医科大学第一附属医院急诊科,广西 南宁 530021)
Author(s):
CHEN Feng1;  SU Qiang2;  ZHU Jijin1; 2
(1.Guangxi Medical University Graduate School ,Nanning 530021,Guangxi,China; 2.Department of Emergency,The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China)
关键词:
高迁移率族蛋白B1; 心脏炎症反应; 心肌炎; 缺血再灌注损伤; 心肌梗死; 心力衰竭
Keywords:
High-mobility gronp box-1;  Cardiac inflammation;  Myocarditis;  Ischemia-reperfusion injury;  Myocardial infarction;  Heart failure
DOI:
10.16806/j.cnki.issn.1004-3934.2019.08.010
摘要:
高迁移率族蛋白B1（HMGB1）是一种广泛存在于真核细胞内的高度保守的核蛋白，释放到核外或细胞外时参与多种疾病的病理过程，包括脓毒症、恶性肿瘤、慢性阻塞性肺病、自身免疫性疾病、动脉粥样硬化和心血管疾病等。大量研究证实：心脏炎症反应是多种心脏疾病发生的重要病理机制，而HMGB1作为一种晚期炎症介质在心肌炎、心肌缺血再灌注损伤、心肌梗死和心力衰竭等心脏疾病中发挥关键作用。现就HMGB1在心脏炎症反应性疾病中的作用进行综述。
Abstract:
High-mobility group box-1(HMGB1) is a highly conserved nuclear protein widely distributed in eukaryotic cells. It is involved in the pathological processes of various diseases when released outside the nucleus or cells. These include sepsis, malignant tumors, chronic obstructive pulmonary disease, autoimmune diseases, atherosclerosis and cardiovascular disease. Numerous studies have confirmed that cardiac inflammatory response is an important pathological mechanism for the development of a variety of heart diseases, and HMGB1, as a late inflammatory mediator, plays a key role in heart disease such as myocarditis,myocardial ischemia-reperfusion injury, myocardial infarction and heart failure. Therefore, this article reviews the role of HMGB1 in cardiac inflammatory diseases

参考文献/References:


[1] Li Q,Li ZM,Sun SY,et al. PARP1 interacts with HMGB1 and promotes its nuclear export in pathological myocardial hypertrophy[J]. Acta Pharmacol Sin,2019,40(5):589-598.
[2] Karuppagounder V,Giridharan VV,Arumugam S,et al. Modulation of macrophage polarization and HMGB1-TLR2/TLR4 cascade plays a crucial role for cardiac remodeling in senescence-accelerated prone mice[J]. PLoS One,2016,11(4):e0152922.[
3] Bangert A, Andrassy M, Muller AM, et al. Critical role of RAGE and HMGB1 in inflammatory heart disease[J]. Proc Natl Acad Sci U S A,2016,113(2):E155-E164.
[4] Zhang L,Liu M,Jiang H,et al. Extracellular high-mobility group box 1 mediates pressure overload-induced cardiac hypertrophy and heart failure[J]. J Cell Mol Med,2016,20(3):459-470.
[5] Dong LY,Chen F,Xu M,et al. Quercetin attenuates myocardial ischemia-reperfusion injury via downregulation of the HMGB1-TLR4-NF-kappaB signaling pathway[J]. Am J Transl Res,2018,10(5):1273-1283.
[6] Jiang Y,Chen R,Shao X,et al. HMGB1 silencing in macrophages prevented their functional skewing and ameliorated EAM development: nuclear HMGB1 may be a checkpoint molecule of macrophage reprogramming [J]. Int Immunopharmacol,2018,56:277-284.
[7] Sato A,Suzuki S,Watanabe S,te al. DPP4 inhibition ameliorates cardiac function by blocking the cleavage of HMGB1 in diabetic mice after myocardial infarction[J]. Int Heart J,2017,58(5):778-786.
[8] Cai J,Wen J,Bauer E,et al. The role of HMGB1 in cardiovascular biology: danger signals[J]. Antioxid Redox Signal,2015,23(17):1351-1369.
[9] Lee SA, Kwak MS, Kim S,et al. The role of high mobility group box 1 in innate immunity [J].Yonsei Med J, 2014,55(5):1165-1176.
[10] Liu T,Zhang D Y,Zhou Y H, et al. Increased serum HMGB1 level may predict the fatal outcomes in patients with chronic heart failure[J]. Int J Cardiol, 2015, 184:318-320.
[11] Srisuwantha R,Shiheido Y,Aoyama N,et al. Porphyromonas gingivalis elevated high-mobility group box 1 levels after myocardial infarction in mice[J]. Int Heart J,2017,58(5): 762-768.
[12] Yao HC,Yang LJ,Han QF,et al. Postconditioning with simvastatin decreases myocardial injury in rats following acute myocardial ischemia [J]. Exp Ther Med,2015,9(4):1166-1170.
[13] Yang L,Wang B,Zhou Q,et al. MicroRNA-21 prevents excessive inflammation and cardiac dysfunction after myocardial infarction through targeting KBTBD7[J]. Cell Death Dis,2018, 9(7):769.
[14] Tong S,Zhang L,Joseph J,et al. Celastrol pretreatment attenuates rat myocardial ischemia/ reperfusion injury by inhibiting high mobility group box 1 protein expression via the PI3K/Akt pathway[J]. Biochem Biophys Res Commun, 2018,497(3):843-849.
[15] Yu Y,Yu Y,Liu M,et al. Ethyl pyruvate attenuated coxsackievirus B3-induced acute viral myocarditis by suppression of HMGB1/RAGE/NF-KappaB pathway[J]. SpringerPlus,2016,5:215.
[16] Qi YF,Zhang J,Wang L,et al. Angiotensin-converting enzyme 2 inhibits high-mobility group box 1 and attenuates cardiac dysfunction post-myocardial ischemia[J]. J Mol Med (Berl),2016,94(1):37-49.
[17] Wang M,Yue Y,Dong C,et al. Mucosal immunization with high-mobility group box 1 in chitosan enhances DNA vaccine-induced protection against coxsackievirus B3-induced myocarditis[J]. Clin Vaccine Immunol,2013,20(11): 1743-1751.
[18] Li J Z,Xie M Q,Mo D,et al. PicrosideⅡ protects myocardium from ischemia/reperfusion-induced injury through inhibition of the inflammatory response[J]. Exp Ther Med,2016,12(6):3507-3514.
[19] Vilahur G,Badimon L.Ischemia/reperfusion activates myocardial innate immune response: the key role of the toll-like receptor[J]. Front Physiol,2014,5:496.
[20] Diao H, Kang Z, Han F,et al. Astilbin protects diabetic rat heart against ischemia-reperfusion injury via blockade of HMGB1-dependent NF-kappaB signaling pathway[J]. Food Chem Toxicol,2014,63:104-110.
21] Tsung A,Tohme S,Billiar TR. High-mobility group box-1 in sterile inflammation[J]. J Intern Med,2014,276(5): 425-443.?
[22] Lin Y,Chen L,Li W,et al. Role of high-mobility group box-1 in myocardial ischemia/reperfusion injury and the effect of ethyl pyruvate[J]. Exp Ther Med,2015,9(4): 537-1541.
[23] Lv Q,Li C,Mo Y,et al. The role of HMGB1 in heart transplantation [J]. Immunol Lett,2018,194:1-3.
[24] Hu X,Jiang H,Cui B,et al. Preconditioning with high mobility group box 1 protein protects against myocardial ischemia–reperfusion injury[J]. Int J Cardiol,2010,145(1),111–112.
[25] Abarbanell A M,Hartley J A,Herrmann J L,et al. Exogenous high-mobility group box 1 improves myocardial recovery after acute global ischemia/reperfusion injury[J]. Surgery,2011,149(3):329-335.
[26] Kitahara T,Takeishi Y,Harada M,et al. High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice[J]. Cardiovasc Res,2008,80(1):40-46.
[27] Takahashi M. High-mobility group box 1 protein in myocardial infarction: should it be stimulated or inhibited? [J]. J Atheroscler Thromb,2015,22(6):553-554.
[28] Bruton M,Hollan I,Xiao J,et al. Expression of high mobility group protein B1 in cardiac tissue of elderly patients with coronary artery disease with or without inflammatory rheumatic disease[J]. Gerontology,2017,63(4):337-349.
[29] Marsh AM,Nguyen AH,Parker TM,et al. Clinical use of high mobility group box 1 and the receptor for advanced glycation end products in the prognosis and risk stratification of heart failure: a literature review[J]. Can J Physiol Pharmacol,2017,95(3):253-259.
[30] Funayama A, Shishido T, Netsu S,et al. Cardiac nuclear high mobility group box 1 prevents the development of cardiac hypertrophy and heart failure[J]. Cardiovasc Res,2013,99(4):657-664.
[31] Hong G,Zheng D,Zhang L,et al. Administration of nicotinamide riboside prevents oxidative stress and organ injury in sepsis[J]. Free Radic Biol Med,2018,123:125-137.
[32] Wu H,Sheng ZQ,Xie J,et al. Reduced HMGB 1-mediated pathway and oxidative stress in resveratrol-treated diabetic mice: a possible mechanism of cardioprotection of resveratrol in diabetes mellitus[J]. Oxid Med Cell Longev, 2016,2016:9836860.
[33] Wang Q,Li RP,Xue FS,et al. Optimal intervention time of vagal stimulation attenuating myocardial ischemia/reperfusion injury in rats[J]. Inflamm Res,2014,63(12):987-999.

更新日期/Last Update: 2020-01-19